Table 3.
Mean (SD) electrolyte and lipid measurements at baseline and last value on treatment
| Placebo N = 12 | Empagliflozin 2.5 mg qd N = 9 | Empagliflozin 10 mg qd N = 9a | Empagliflozin 25 mg qd N = 9 | Empagliflozin 100 mg qd N = 9 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Last value on treatment | Baseline | Last value on treatment | Baseline | Last value on treatment | Baseline | Last value on treatment | Baseline | Last value on treatment | |
| Electrolytes (mmol/l) | ||||||||||
| Sodium | 140 (3) | 140 (3) | 140 (2) | 140 (2) | 141 (1) | 140 (1) | 139 (2) | 139 (2) | 138 (2) | 139 (2) |
| Potassium | 4.3 (0.4) | 4.4 (0.4) | 4.1 (0.3) | 4.2 (0.3) | 4.2 (0.2) | 4.4 (0.3) | 4.1 (0.2) | 4.1 (0.3) | 4.5 (0.4) | 4.5 (0.3) |
| Calcium | 2.3 (0.1) | 2.3 (0.1) | 2.3 (0.1) | 2.3 (0.1) | 2.3 (0.1) | 2.3 (0.1) | 2.3 (0.1) | 2.3 (0.1) | 2.4 (0.1) | 2.3 (0.1) |
| Total cholesterol (mg/dL) | 179 (16) | 173 (7) | 181 (9) | 175 (11) | 173 (27) | 171 (25) | 185 (15) | 174 (13) | 181 (9) | 174 (11) |
| HDL-cholesterol (mg/dL) | 43 (22) | 31 (16) | 15 (21) | 16 (18) | 46 (29) | 31 (18) | 47 (12) | 41 (17) | 42 (19) | 37 (18) |
| Triglycerides (mg/dL) | 177 (121) | 143 (89) | 249 (109) | 171 (65) | 194 (145) | 114 (42) | 141 (67) | 89 (26) | 157 (43) | 97 (27) |
Values are normalized to a standard reference range
SD standard deviation, HDL high-density lipoprotein
a N = 8 for HDL-cholesterol